OakChart

MeiraGTx Holdings plc

MGTXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

9.68+0.06 (0.62%)
2026-11-12 04:03 CET
Market cap
929.70 USD m
Revenue, TTM
397.50 USD m
Net income, TTM
78.98 USD m
Free cash flow, TTM
10.47 USD m
EPS diluted, TTM
0.71
P/E
13.72
Compare

Price

MGTX against its 20, 50 and 200-day averages
2050200beatmiss
8.0010.0012.0014.002.4M4.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MGTXclose 9.6820-day 9.4850-day 10.91200-day 10.379.6852w high

36.9% under the 52-week high of 15.35 on 7 Jul 2026. 52-week low 6.62 on 5 Mar 2026. Last 15 sessions, 19.2% high to low

Volume 0.56× normal · the line is the 50-bar volume average

Profile

MGTX
52-week range, 35% of the way up
6.6215.35

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson's disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.

IndexRUT
Employees403
IPOJun 08, 2018
Beta1.07
ATR, 14d0.51
Rel volume0.56
Short float9.02%
Insider own23.34%
Inst own65.18%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap929.69M
Enterprise Value899.05M
Income78.98M
Sales397.50M
Book/sh2.29
Cash/sh1.49
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees403
IPOJun 08, 2018

Ratios

P/E13.72
Forward P/E-
PEG-
P/S2.34
P/B4.23
P/C6.49
P/FCF88.80
EV/EBITDA4.62
EV/Sales2.26
Quick Ratio3.76
Current Ratio3.76
Debt/Eq0.52
LT Debt/Eq0.51
Option/ShortYes / Yes

Earnings

EPS (ttm)0.71
EPS next Y-1.75
EPS next Q-0.50
EPS this Y121.13%
EPS next Y-683.81%
EPS next 5Y5.92%
EPS past 3/5Y20.90% 1.58%
Sales past 3/5Y72.27% 39.22%
EPS Y/Y TTM136.80%
Sales Y/Y TTM948.35%
EPS Q/Q455.90%
Sales Q/Q8608.59%
EarningsAug 13 BMO
EPS/Sales Surpr.473.12% 45819.14%

Ownership

Insider Own23.34%
Insider Trans-1.28%
Inst Own65.18%
Inst Trans14.30%
ROA26.54%
ROE72.28%
ROIC24.26%
Gross Margin94.90%
Oper. Margin45.94%
Profit Margin19.87%
SMA202.16%
SMA50-11.30%
SMA200-6.65%
Trades-

Technical

Shs Outstand94.19M
Shs Float73.63M
Short Float9.02%
Short Ratio8.10
Short Interest6.64M
52W High15.35 -36.94%
52W Low6.62 46.22%
Volatility6.44% 5.49%
ATR (14)0.51
RSI (14)47.36
Beta1.07
Rel Volume0.56
Avg Volume819.70K
Volume455,976

Performance

Perf Week2.76%
Perf Month-2.62%
Perf Quarter-23.60%
Perf Half Y-2.91%
Perf YTD21.76%
Perf Year8.76%
Perf 3Y101.25%
Perf 5Y-51.14%
Perf 10Y-
Recom1.25
Target Price27.75
Prev Close9.62
Price9.68
Change %0.62%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Sep 24, 2026InitiatedGGoldmanNeutral$16+65.3%
Nov 24, 2025InitiatedHH.C. WainwrightBuy$20+106.6%
Oct 21, 2025InitiatedRRaymond JamesStrong Buy$29+199.6%
Jul 31, 2024ResumedCChardan Capital MarketsBuy$36+271.9%
Oct 23, 2020InitiatedRRBC Capital MktsOutperform$27+178.9%
Sep 15, 2020ResumedBBofA SecuritiesBuy$20+106.6%
Sep 03, 2019InitiatedPPiper JaffrayOverweight$40+313.2%
Feb 27, 2019ReiteratedCChardan Capital MarketsBuy$30 → $40+313.2%
Jul 03, 2018InitiatedBBofA/MerrillBuy
Jul 03, 2018InitiatedBBarclaysOverweight

Peers

Mkt cap
TickerCompanyMkt cap
RGNXRegenxbio Inc560.06M
FDMT4D Molecular Therapeutics Inc717.62M
QUREuniQure NV1.72B
ABEOAbeona Therapeutics Inc131.44M
IRDOpus Genetics Inc358.58M
OCGNOcugen Inc325.87M
RCKTRocket Pharmaceuticals Inc272.24M
VYGRVoyager Therapeutics Inc109.53M
SLDBSolid Biosciences Inc848.24M
KRYSKrystal Biotech Inc9.15B

Insider trading

latest 14 of 18
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Giroux RichardCFO & COOOct 20 '26Sale9.9556,000557,200852,530Oct 20 08:57 PM
Richard GirouxOfficerOct 20 '26Proposed Sale9.9556,000557,200Oct 20 08:56 PM
Naylor StuartCHIEF SCI OFCR, OPHTHALMOLOGYOct 06 '26Sale10.6427,659294,292613,187Oct 06 08:53 PM
Naylor StuartOfficerOct 06 '26Proposed Sale10.6427,659294,321Oct 06 04:20 PM
Forbes AlexandriaPRESIDENT & CEOAug 18 '26Sale13.8662,000859,3201,325,695Aug 18 09:03 PM
Alexandria ForbesOfficerAug 18 '26Proposed Sale13.8662,000859,320Aug 18 09:01 PM
Giroux RichardCFO & COOJul 21 '26Sale12.5156,000700,560908,530Jul 21 09:12 PM
Richard GirouxOfficerJul 21 '26Proposed Sale12.5156,000700,560Jul 21 09:09 PM
Naylor StuartCHIEF SCI OFCR, OPHTHALMOLOGYJul 07 '26Sale14.8027,659409,470640,846Jul 07 09:05 PM
Naylor StuartOfficerJul 07 '26Proposed Sale13.3327,659368,694Jul 07 09:45 AM
Forbes AlexandriaPRESIDENT & CEOMay 19 '26Sale9.1762,000568,5401,387,695May 19 09:05 PM
Alexandria ForbesOfficerMay 19 '26Proposed Sale9.1762,000568,540May 19 09:03 PM
Giroux RichardCFO & COOApr 21 '26Sale10.2256,000572,320971,530Apr 21 09:01 PM
Richard GirouxOfficerApr 21 '26Proposed Sale10.2256,000572,545Apr 21 08:59 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
FYCFirst Trust Small Cap Growth AlphaDEX FundAUM: 1.35B
IBBiShares Biotechnology ETFAUM: 11.36B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
KOMPState Street SPDR S&P Kensho New Economies Composite ETFAUM: 2.46B
JSMLJanus Henderson Small Cap Growth Alpha ETFAUM: 377.91M
FYXFirst Trust Small Cap Core AlphaDEX FundAUM: 1.39B
VHTVanguard Health Care ETFAUM: 21.51B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting (GlobeNewswire)
  • MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors (GlobeNewswire)
  • Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical (PR Newswire)
  • MeiraGTx Reports Second Quarter 2026 Financial and Operational Results (GlobeNewswire)
  • MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec) (GlobeNewswire) +5.54%
  • MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.53%
  • MeiraGTx Reports First Quarter 2026 Financial and Operational Results (GlobeNewswire)
  • Miami International, Nathan's Famous, and 3 More Stocks See Action From Activist Investors (Barrons.com)
  • MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares (GlobeNewswire) -15.73%
  • MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) (GlobeNewswire)
  • MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia (GlobeNewswire)
  • MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026 (GlobeNewswire) +17.24%
  • MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-131.710-0.4581.710321.430.706
2026Q12026-05-14-0.570-0.606-0.5700.2917.005
2025Q42026-03-260.190-0.5700.18675.361.456
2025Q32025-11-13-0.620-0.490-0.6240.416.975
2025Q22025-08-14-0.480-0.468-0.4813.696.484
2025Q12025-05-13-0.510-0.487-0.5061.934.443
2024Q42025-03-13-0.490-0.530-0.50321.391.103
2024Q32024-11-13-0.550-0.563-0.54910.911.203
2024Q22024-08-12-0.760-0.400-0.7550.289.702
2024Q12024-05-09-0.320-0.505-0.3190.709.702
2023Q42024-03-140.4000.0250.3182.056.564
2023Q32023-11-14-0.740-0.547-0.7445.103.273
2023Q22023-08-10-0.530-0.548-0.5343.544.174
2023Q12023-05-11-0.620-0.657-0.6243.334.873
2022Q42023-03-14-0.580-0.504-0.580-5.298.935
2022Q32022-11-10-0.830-0.582-0.8344.8210.906

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.650-2.027-1.65113.296.50
2020FY-1.540-1.581-1.53715.5617.16
2021FY-1.800-2.060-1.80337.7022.77
2022FY-2.870-2.687-2.86915.9232.75
2023FY-1.490-1.682-1.48814.0240.40
2024FY-2.120-1.950-2.11733.2816.51
2025FY-1.420-1.698-1.42081.3924.51
2026FY-0.300--337.12
2027FY--1.751--66.89
2028FY--1.183--155.24
2029FY--0.427--284.56
2030FY-1.117--589.84

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-277006.951.5017.50
2026Q3S2026-09-237306.951.5017.50
2026Q3S2026-08-136307.071.5017.50
2026Q3S2026-07-306201.570.004.92
2026Q3S2026-07-067205.870.0031.70
2026Q3S2026-06-097025.790.0031.70
2026Q3S2026-05-147035.790.0031.70
2026Q3S2026-04-177115.950.0031.70
2026Q3S2026-04-156116.690.0031.70
2026Q3S2026-03-266026.680.0031.70
2026Q3S2026-01-2740045.560.00180.32
2026Q3S2025-11-2140145.560.00180.32
2026Q3S2025-11-1330160.240.00180.32
2026Q3S2025-11-1130061.340.00180.32

Estimate history

EPS, annual-1.14-4.469-1.651-1.537-1.803-2.869-1.488-2.117-1.420.7057
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.755-0.549-0.503-0.506-0.481-0.6240.186-0.571.713
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0013.29215.56337.70115.9214.01733.27981.391397.5
Period201720182019202020212022202320242025TTM
Sales, quarterly0.28210.9121.391.9263.6910.4175.3640.293321.434
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual27.93427.38736.79244.18944.54948.47763.60178.39781.12194.188
Period201720182019202020212022202320242025MRQ
Shares, quarterly64.68477.69578.39779.41880.44680.4881.12181.44694.188
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue397.5081.3933.2814.0215.9237.7015.5613.290.00
Cost of Goods Sold Incl. D&A20.2517.3936.6213.738.727.87--2.05
Gross Profit377.2564.01-3.340.297.2029.83---2.05
Selling, General and Administrative Excl. Other194.62171.37160.87137.35123.55103.0273.9568.2176.05
Research and Development153.16129.32119.18103.4885.5366.8333.9124.8833.62
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income182.63-107.37-164.21-137.06-116.36-73.19-62.55-58.27-78.10
Interest Expense12.4812.2013.2713.244.950.290.140.050.03
Unusual Expense-1.40-1.400.00-0.500.000.000.000.001.51
Net Income Before Taxes81.29-114.20-147.79-84.03-129.62-79.56-57.99-54.75-83.34
Income Taxes2.360.000.000.000.000.000.000.00-0.47
Consolidated Net Income78.93-114.20-147.79-84.03-129.62-79.56-57.99-54.75-82.87
Net Income From Continuing Operations78.98-114.20-147.79-84.03-129.62-79.56-57.99-54.75-82.87
Net Income78.98-114.20-147.79-84.03-129.62-79.56-57.99-54.75-84.67
EPS (Recurring)0.83-1.43-2.12-1.49-2.87-1.80-1.54-1.65-4.41
EPS (Basic, Before Extraordinaries)0.75-1.42-2.12-1.49-2.87-1.80-1.54-1.65-4.47
EPS (Diluted)0.71-1.42-2.12-1.49-2.87-1.80-1.54-1.65-4.47
EBITDA194.73-94.83-151.38-123.33-107.63-65.32-58.38-54.92-76.05
Non-Operating Income (Expense)-90.263.9629.6965.78-8.31-6.084.703.57-3.69
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense18.1922.1125.1927.7228.6220.7818.4211.6314.13
Price To Earnings Ratio13.7213.72-------
Price To Sales Ratio3.197.8612.7828.2918.5027.7936.7049.95-
Gross Margin94.9078.64-10.042.0545.2179.12---
Operating Margin45.94-131.92-493.44-977.82-730.87-194.14-401.94-438.37-
Net Margin19.87-140.31-444.10-599.46-814.16-211.03-372.63-411.87-
Shares Outstanding94.1981.1278.4063.6048.4844.5544.1936.7927.39
Market Capitalization929.70929.70475.95446.45291.611,055.21657.26732.17264.01

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue321.430.2975.360.413.691.9321.3910.91
Cost of Goods Sold Incl. D&A9.993.213.593.475.874.4614.8815.24
Gross Profit311.45-2.9171.77-3.06-2.17-2.536.51-4.33
Selling, General and Administrative Excl. Other67.0237.9046.7042.9942.6239.0638.0035.71
Research and Development57.8331.9830.8132.5333.4932.7823.6826.24
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income244.43-40.8225.07-46.05-44.79-41.60-31.49-40.04
Interest Expense3.512.853.063.063.033.043.413.36
Unusual Expense0.000.00-1.400.000.000.000.000.00
Net Income Before Taxes163.03-46.3115.09-50.51-38.80-39.98-39.40-39.33
Income Taxes2.360.000.000.000.000.000.000.00
Consolidated Net Income160.67-46.3115.09-50.51-38.80-39.98-39.40-39.33
Net Income From Continuing Operations160.72-46.3115.09-50.51-38.80-39.98-39.40-39.33
Net Income160.72-46.3115.09-50.51-38.80-39.98-39.40-39.33
EPS (Recurring)1.71-0.570.17-0.62-0.48-0.51-0.50-0.55
EPS (Basic, Before Extraordinaries)1.76-0.570.19-0.62-0.48-0.51-0.50-0.55
EPS (Diluted)1.71-0.570.19-0.62-0.48-0.51-0.50-0.55
EBITDA247.25-37.8128.19-42.90-41.60-38.52-28.42-36.78
Non-Operating Income (Expense)-77.89-2.65-8.33-1.409.034.66-4.504.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.993.655.605.955.664.896.126.30
Price To Earnings Ratio13.72-------
Price To Sales Ratio3.198.837.9224.3013.8615.5314.3521.45
Gross Margin96.89-994.2095.24-746.10-58.93-131.5230.45-39.73
Operating Margin76.04-13,930.7233.27-11,231.95-1,213.57-2,159.71-147.22-367.01
Net Margin50.00-15,806.4820.02-12,320.24-1,051.07-2,075.86-184.19-360.49
Shares Outstanding94.1981.4581.1280.4880.4579.4278.4077.70
Market Capitalization929.70697.05639.90662.08523.98534.64475.95322.75

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments65.93103.66129.57115.52137.70209.52227.2368.088.55
Short Term Receivables18.2910.6323.4129.0235.0255.4137.110.000.00
Inventories0.000.390.000.000.000.000.000.000.00
Other Current Assets7.548.856.649.8010.527.654.636.572.93
Total Current Assets91.76123.52159.62154.34183.24272.58268.9874.6511.48
Net Property, Plant & Equipment141.93135.65156.24154.09126.2987.1252.8622.0114.26
Total Investments and Advances9.018.767.856.336.660.000.120.120.12
Intangible Assets0.580.821.122.082.572.970.780.000.00
Deferred Tax Assets6.61-131.42------
Other Assets1.151.001.921.401.401.031.150.110.00
Total Assets251.04269.75458.17318.24320.16363.70323.8996.8925.85
Short Term Debt Incl. Current Port. of LT Debt27.544.054.193.883.372.581.670.031.47
Accounts Payable10.0723.5916.0416.6215.357.133.763.047.06
Other Current Liabilities84.9533.1446.8461.5749.4144.4343.7612.4312.87
Total Current Liabilities122.5660.7867.0882.0768.1354.1549.2015.5021.40
Long Term Debt61.1580.7485.0788.3620.3619.6721.500.010.03
Provision for Risks Charges1.402.822.402.182.081.811.650.130.00
Deferred Tax Liabilities6.61-131.420.190.200.210.20--
Other Liabilities65.1257.5834.0227.7044.0049.3060.540.200.44
Total Liabilities256.83201.92319.99200.50134.76125.14133.0915.8421.88
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.0051.34
Common Equity-5.7967.83138.18117.74185.40238.56190.8081.06-47.37
Total Shareholders Equity-5.7967.83138.18117.74185.40238.56190.8081.063.97
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-5.7967.83138.18117.74185.40238.56190.8081.063.97
Total Liabilities & Stockholders Equity251.04269.75458.17318.24320.16363.70323.8996.8925.85
Book Value Per Share-0.070.872.172.434.165.405.192.96-1.70
Tangible Book Value Per Share-0.080.852.152.394.105.335.162.96-1.70
Full-Time Employees4033814253582962191576859
Price to Book Ratio4.234.944.552.055.702.803.863.262.72
Return on Assets-43.86-40.61-21.65-40.61-23.27-16.87-26.02-135.02-128.27
Return on Equity-368.19-143.48-65.67-85.52-37.53-27.01-40.28-194.90-315.69
Return on Invested Capital-206.30-99.47-37.64-62.89-38.67-22.46-25.79-102.22-774.63
Quick Ratio0.752.032.381.882.695.035.474.820.54
Current Ratio0.752.032.381.882.695.035.474.820.54

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income78.93-114.20-147.79-84.03-129.62-79.56-57.99-54.75-82.87
Depreciation12.1012.5412.8313.738.727.874.173.352.05
Other Funds (Non Cash)43.6527.270.82-34.0938.1729.8822.4914.7225.84
Funds from Operations134.68-74.39-134.14-104.38-82.72-41.81-31.33-36.68-54.97
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-121.0028.0329.64-0.989.6231.28-32.6456.73-3.92
Cash from Operating Activities13.69-46.36-104.50-105.36-73.10-10.53-63.9720.04-58.89
Capital Expenditures-3.63-4.24-4.96-20.17-44.96-55.22-37.02-8.98-11.26
Net Assets From Acquisitions0.000.000.000.000.000.000.00-0.39-
Sale of Fixed Assets and Businesses0.330.1328.4354.210.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.00-6.500.000.000.00
Purchase of Investments0.000.000.000.000.00-6.500.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses-24.230.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-27.53-4.1123.4834.03-44.96-61.72-37.02-9.37-11.26
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock110.1415.2956.8785.5425.231.7182.75148.26131.51
Repurchase of Common Pref Stock-18.190.000.000.000.000.000.000.000.00
Sale of Common Pref Stock128.3315.2956.8785.5425.231.7182.75148.26131.51
Proceedsfrom Stock Options127.2815.0456.8785.5325.000.0081.91147.70121.79
Issuance or Reduction of Debt, Net24.94-0.030.000.0072.74-0.00-0.02-0.02-1.47
Change in Long Term Debt24.94-0.030.000.0072.74-0.00-0.02-0.02-1.47
Issuance of Long Term Debt100.000.000.000.0072.740.000.000.000.00
Reduction of Long Term Debt-75.06-0.030.000.000.00-0.00-0.02-0.02-1.47
Net Financing Active Other Cash Flow-6.19-2.99-2.34-1.52-2.770.000.000.000.00
Other Financing Activities Uses-6.19-2.99-2.34-1.52-2.770.000.000.000.00
Cash from Financing Activities128.8912.2754.5384.0295.201.7182.73148.23130.04
Exchange Rate Effect-4.110.721.502.440.67-1.280.420.24-0.36
Net Change in Cash110.94-37.48-24.9815.13-22.19-71.82-17.84159.1559.53
Free Cash Flow10.47-50.19-109.45-125.54-118.06-65.75-98.8611.06-70.15
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Price to Free Cash Flow121.08------60.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments143.1771.5465.9314.8432.1766.52
Short Term Receivables44.2617.9618.2911.816.795.22
Inventories0.000.000.000.000.310.61
Other Current Assets30.926.707.547.527.817.53
Total Current Assets218.3596.2091.7634.1747.0879.89
Net Property, Plant & Equipment134.28137.53141.93144.52140.79133.48
Total Investments and Advances42.048.979.019.019.018.84
Intangible Assets0.420.490.580.650.740.77
Deferred Tax Assets--6.61---
Other Assets1.361.471.151.111.091.03
Total Assets396.45244.66251.04189.47198.72224.01
Short Term Debt Incl. Current Port. of LT Debt2.3027.1327.5476.532.653.30
Accounts Payable11.6716.6610.0721.5425.5920.29
Income Tax Payable2.36-----
Other Current Liabilities41.77132.3484.9554.8525.2028.79
Total Current Liabilities58.10176.13122.56152.9253.4452.37
Long Term Debt110.0260.4161.1511.5377.8277.58
Provision for Risks Charges1.451.411.401.361.451.34
Deferred Tax Liabilities--6.61---
Other Liabilities11.1064.8465.1264.2163.0459.62
Total Liabilities180.67302.79256.83230.03195.76190.91
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity215.57-58.13-5.79-40.562.9633.10
Total Shareholders Equity215.57-58.13-5.79-40.562.9633.10
Accumulated Minority Interest0.210.000.000.000.000.00
Total Equity215.78-58.13-5.79-40.562.9633.10
Total Liabilities & Stockholders Equity396.45244.66251.04189.47198.72224.01
Book Value Per Share2.29-0.71-0.07-0.500.040.42
Tangible Book Value Per Share2.28-0.72-0.08-0.510.030.41
Full-Time Employees393409403---
Price to Book Ratio4.23-121.27-15.78223.7015.647.84
Return on Assets26.54-51.44-43.86-69.00-67.69-62.76
Return on Equity72.28--368.19-611.42-379.53-216.14
Return on Invested Capital49.36-2,033.9527.26--48.02-36.12
Quick Ratio3.760.550.750.220.881.51
Current Ratio3.760.550.750.220.881.53

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income160.67-46.3115.09-50.51-38.80-39.98
Depreciation2.823.013.123.163.193.08
Other Funds (Non Cash)5.697.9621.798.22-2.860.12
Funds from Operations169.18-35.3439.99-39.14-38.46-36.78
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-207.7253.156.6426.92-5.49-0.05
Cash from Operating Activities-38.5417.8146.63-12.21-43.95-36.83
Capital Expenditures-0.33-2.01-0.68-0.61-1.23-1.71
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.680.00-0.410.060.470.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses-23.98-0.250.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-23.63-2.26-1.09-0.55-0.76-1.71
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock108.91-4.145.360.015.454.47
Repurchase of Common Pref Stock0.00-18.190.000.000.000.00
Sale of Common Pref Stock108.9114.055.360.015.454.47
Proceedsfrom Stock Options108.1413.995.150.005.424.47
Issuance or Reduction of Debt, Net24.98-0.01-0.030.000.000.00
Change in Long Term Debt24.98-0.01-0.030.000.000.00
Issuance of Long Term Debt100.000.000.000.000.000.00
Reduction of Long Term Debt-75.02-0.01-0.030.000.000.00
Net Financing Active Other Cash Flow0.00-5.960.00-0.230.00-2.76
Other Financing Activities Uses0.00-5.960.00-0.230.00-2.76
Cash from Financing Activities133.89-10.115.33-0.225.451.71
Exchange Rate Effect-0.110.130.22-4.345.07-0.23
Net Change in Cash71.615.5751.09-17.32-34.19-37.06
Free Cash Flow-38.8715.8046.36-12.82-45.18-38.54
Price to Free Cash Flow121.08169.45----

Revenue breakdown

License2025: 74.99M
Related Party Service2024: 33.28M 2025: 6.40M
United States2024: 33.28M 2025: 81.39M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.02%6.6M73.6M800.86K
2026-10-158.74%6.4M73.6M775.54K
2026-09-308.15%6.0M73.6M797.54K
2026-09-155.45%4.0M73.6M848.91K
2026-08-315.11%3.7M72.8M837.05K
2026-08-145.14%3.7M72.8M872.12K
2026-07-315.56%3.9M70.1M877.95K
2026-07-156.01%4.2M70.1M1.04M
2026-06-306.73%4.7M70.1M991.96K
2026-06-157.92%5.5M70.1M828.21K
2026-05-296.06%5.4M89.0M804.48K
2026-05-157.76%5.4M70.1M693.40K
2026-04-308.60%5.7M66.6M670.56K
2026-04-156.95%4.6M66.6M507.41K
2026-03-318.80%5.2M58.5M444.38K
2026-03-139.16%5.3M57.8M399.93K
2026-02-278.77%5.1M57.8M425.05K
2026-02-138.97%5.2M57.8M485.83K
2026-01-309.42%5.4M57.9M531.93K
2026-01-159.86%5.7M57.9M529.05K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.504.709.500.0026.6490.000.000.971-0.0340.001
call5.002.307.000.0010.8260.000.000.942-0.0330.002
call7.500.404.904.256.4731.000.000.765-0.1400.005
call10.000.004.902.308.13311.000.000.730-0.2310.005
call12.500.050.950.353.03334.0060.000.381-0.0990.006
call15.000.004.900.442.21510.000.000.137-0.0410.003
call17.500.004.900.002.8780.000.000.137-0.0540.003
call20.000.004.900.003.2840.000.000.124-0.0570.003
call22.500.003.500.003.6570.000.000.116-0.0610.003
call25.000.003.800.003.9650.000.000.110-0.0640.003
put2.500.004.900.000.0000.000.00-0.005-0.0350.000
put5.000.004.900.103.2292060.00-0.058-0.0320.002
put7.500.001.800.055.3510.001.00-0.235-0.1400.005
put10.000.254.901.508.3161.000.00-0.270-0.2300.005
put12.501.005.700.006.3030.000.00-0.619-0.0970.006
put15.003.007.900.006.6360.000.00-0.863-0.0400.003
put17.505.7010.400.007.2820.000.00-0.863-0.0520.003
put20.008.0012.900.007.8110.000.00-0.893-0.0470.003
put22.5010.5015.200.007.9170.000.00-0.884-0.0580.003
put25.0013.2017.900.008.6320.000.00-0.890-0.0610.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-204Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-20144Filing for proposed sale of securities under Rule 144.SEC
2026-10-06144Filing for proposed sale of securities under Rule 144.SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-243Initial statement of beneficial ownership of securities2026-09-23SEC
2026-09-238-KCurrent report2026-09-22SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-21SEC
2026-07-21144Filing for proposed sale of securities under Rule 144.SEC
2026-07-07144Filing for proposed sale of securities under Rule 144.SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-078-KCurrent report2026-06-30SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000851.49K2
2026-090000
2026-0800859.32K1
2026-07001.11M2
2026-060000
2026-0500568.54K1
2026-0400831.23K2
2026-0300459.42K1
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Sanofi12.70%
PERCEPTIVE ADVISORS LLC11.65%
Rubric Capital Management LP9.83%
JOHNSON & JOHNSON6.91%
BlackRock, Inc.5.14%
ADAGE CAPITAL PARTNERS GP, L.L.C.4.75%
Opaleye Management Inc.3.83%
MILLENNIUM MANAGEMENT LLC3.21%
683 Capital Management, LLC2.48%
Woodline Partners LP1.62%

Funds

Fund% owned
iShares Russell 2000 ETF1.63%
Fidelity Small Cap Index Fund0.71%
Nuveen Quant Small Cap Equity Fund0.57%
iShares Biotechnology ETF0.53%
Janus Henderson Small Cap Growth Alpha ETF0.47%
iShares Russell 2000 Growth ETF0.47%
VANGUARD RUSSELL 2000 INDEX FUND0.36%
Janus Henderson Small/Mid Cap Growth Alpha ETF0.33%
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF0.28%
iShares Micro-Cap ETF0.21%

OakChart. MGTX. Cached 15 minutes.